Physician profile
Adele M Guernica
NPI 1073547048
$2,964.84
in general payments reported to CMS, 2019-2025
25 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $232 · 2021: $643 · 2022: $630 · 2023: $415 · 2024: $302 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $385.80 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $371.51 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $311.51 | 2019-2025 | Dupixent |
| Pfizer INC. | $227.45 | 2020-2025 | |
| Genzyme Corporation | $223.84 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $148.46 | 2020-2025 | |
| Optinose US, INC. | $135.92 | 2020-2025 | |
| Kaleo, INC. | $102.99 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $99.13 | 2021-2025 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $82.92 | 2020-2022 | |
| Grifols USA, LLC | $68.95 | 2020-2022 | |
| Leo Pharma INC. | $68.37 | 2022-2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.09 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.49 | 2021-2023 | |
| Csl Behring | $35.38 | 2022-2023 | Hizentra |
| Biocryst US Sales Co., LLC | $24.92 | 2023 | Orladeyo |
| Hikma Pharmaceuticals USA | $23.87 | 2025 | Ryaltris |
| Blueprint Medicines Corporation | $23.05 | 2023 | Ayvakit |
| Abbvie INC. | $20.83 | 2022 | |
| Amgen INC. | $19.21 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.28 | 2021 | |
| Aytu Biopharma, INC. | $12.81 | 2021 | |
| Aimmune Therapeutics, INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adele Guernica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.